Minodronic acid

Minodronic acid

Minodronic acid (also known as Recalbon and Minodronate) is a bisphosphonate used in the treatment of osteoporosis. It is marketed by Ono Pharmaceutical.

Chemistry

Minodronic acid is a third-generation bisphosphonate, which is a class of drugs that bind to the hydroxyapatite found in bones and prevent their breakdown. It is a derivative of imidazole, and its chemical structure is characterized by the presence of a phosphonic acid group and a hydroxy group on the carbon atom adjacent to the nitrogen atom in the imidazole ring.

Pharmacology

Minodronic acid works by inhibiting osteoclast activity, thereby reducing bone resorption and turnover. It binds to hydroxyapatite and is then taken up by osteoclasts. The drug interferes with the osteoclast's ability to form the ruffled border, which is necessary for bone resorption. This leads to an overall decrease in the breakdown of bone.

Clinical use

Minodronic acid is used in the treatment of osteoporosis to prevent fractures. It is also used in the treatment of Paget's disease of bone, a condition that results in enlarged and misshapen bones. The drug is typically administered orally.

Side effects

Common side effects of minodronic acid include nausea, abdominal pain, and constipation. In rare cases, it can cause more serious side effects such as osteonecrosis of the jaw and atypical femoral fracture.

See also

• Bisphosphonate
• Osteoporosis
• Paget's disease of bone

This article is a stub related to pharmacology. You can help WikiMD by expanding it!